Chronic Kidney Disease

REMODEL offers new mechanistic insights into semaglutide, highlighting microvascular and endothelial effects that help explain its kidney and cardiovascular benefits.

Experts discuss major advances in glomerular disease research and care, including molecular technologies, biomarker discovery, APOL1-mediated kidney disease, and evolving clinical trial design and endpoints.

Neuen reflects on new FIND-CKD data suggesting finerenone’s benefit in nondiabetic chronic kidney disease and highlights urgency of early screening and combination therapy.

Data from 39 kidney biopsies may challenge longterm beliefs about diabetic nephropathy in CKD.

Should clinicians consider neighborhood disadvantage the same way they measure proteinuria and GFR for kidney health?

KDIGO Launches Focused Update to 2024 CKD Guideline on Emerging Therapies

Allocating lower but acceptable quality kidneys to high-risk patients could introduce equity.

Phase 3 FIND-CKD shows finerenone slows non-diabetic CKD decline by improving eGFR slope; Bayer prepares FDA filing for expanded use.

New CKD therapies and a cardiometabolic care model are reshaping kidney disease management.

Experts discuss gaps in CKD detection, the role of albuminuria testing, and the need for earlier, risk-based care to improve outcomes.

7 experts come together to address neighborhood disadvantage and its impact on kidney health in the latest Crisis Point.

Yu, MD, Adler, MD, share their perspectives from a cohort study on in-sequence, and out of sequence paired kidneys transplants.

Salvatore Viscomi, MD on closing CKD health disparities through community testing, AI equity, and accessible care for underserved populations.

Having a primary care provider may be associated with reduced emergency department utilization for patients with ESKD receiving dialysis, according to new research.

An economic model suggest using lower quality, but acceptable kidneys for older adults may be cost efficective and clinically valuable.

Brown discusses a destigmatised future of obesity management in patients with kidney failure.

1 year into real-world use, 4 clinicians discuss how semaglutide is transforming the endocrinology, nephrology, and cardiology landscape.

Experts in nephrology explain the benefits of kidney transplantation, the evolving immunosuppression landscape, and evaluate the risk factors for donors.

Experts discuss shifting CKD detection upstream, improving albuminuria screening, and enabling earlier, risk-based intervention.

FLOW/SELECT suggest. GLP-1 receptor agonists may protect kidneys beyond glucose control

Obesity is common in CKD and drives hyperfiltration, nephron stress, and progressive kidney injury, according to experts, Kramer and Perkovic, and trial data.

With the acceptance, the FDA has assigned the oral phosphate binder a Prescription Drug User Fee Act target action date of June 29, 2026.

Tim Pflederer, explains how nephrologists can help patients with CKD and ESKD navigate the 2025–2030 Dietary Guidelines, including managing protein, potassium, and phosphorus intake.